Arrowhead's SHASTA-10 extension study for plozasiran stays active, not recruiting
The Phase 3 open-label extension trial of plozasiran in hypertriglyceridemia patients remains active but closed to new enrollment as of its October 2026 update.
Arrowhead Pharmaceuticals' registry record for this extension study shows no change in recruitment status for the week.
- "A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia" (SHASTA-10, NCT06822790) is listed as active, not recruiting, with an actual enrollment of 710 participants1. The study enrolls participants who had a baseline fasting TG level of ≥1000 mg/dL at the time of enrollment into AROAPOC3-20011 or met other criteria from related parent studies, and primary completion is estimated for July 2028.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.